Observation of Heavy-Chain C-Terminal Amidation in Human Endogenous IgG.

Autor:	Shah B; Process Development, Amgen Inc. One Amgen Center Drive, Thousand Oaks, CA 91320, USA., Li M; Quality, Amgen Inc. One Amgen Center Drive, Thousand Oaks, CA 91320, USA., Wypych J; Process Development, Amgen Inc. One Amgen Center Drive, Thousand Oaks, CA 91320, USA., Joubert MK; Process Development, Amgen Inc. One Amgen Center Drive, Thousand Oaks, CA 91320, USA., Zhang Z; Process Development, Amgen Inc. One Amgen Center Drive, Thousand Oaks, CA 91320, USA. Electronic address: zzhang@amgen.com.
Jazyk:	angličtina
Zdroj:	Journal of pharmaceutical sciences [J Pharm Sci] 2022 Sep; Vol. 111 (9), pp. 2445-2450. Date of Electronic Publication: 2022 Jun 16.
DOI:	10.1016/j.xphs.2022.06.012
Abstrakt:	Therapeutic IgG mAbs expressed from Chinese hamster ovary (CHO) cells are known to contain three C-terminal variants in their heavy chains, namely, the unprocessed C-terminal lysine, the processed C-terminal lysine, and C-terminal amidation. Although the presence of C-terminal amidation in CHO-expressed IgGs is well studied, the biological impact of the variant on the safety and efficacy of biotherapeutics has not been well understood. To further our biological understanding of C-terminal amidation, we analyzed a series of IgG samples, including both endogenous human IgGs as well as recombinant IgGs of different subclasses expressed from both CHO and murine cell lines, for their heavy-chain C-terminal variants by LC-MS/MS based peptide mapping. The results demonstrate that heavy-chain C-terminal amidation is a common variant occurring in IgG of all four subclasses (IgG1, IgG2, IgG3 and IgG4). The variant is generally present in recombinant IgG mAbs expressed from CHO cell lines but not in IgG mAbs expressed from murine cell lines, whereas the IgGs expressed from murine cell lines contain a much larger amount of unprocessed C-terminal lysine. Additionally, a significant amount of heavy-chain C-terminal amidation is observed in endogenous human IgGs, indicating that small amount of the variant present in therapeutic IgGs does not pose a safety concern. (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu